Geoffrey Teixeira

Company: Alentis Therapeutics

Job title: Senior Vice President & Head of Fibrosis

Seminars:

Examining Anti-Claudin-1 (CLDN1) Monoclonal Antibodies in Development for Liver, Kidney & Lung Fibrosis as a Novel Mechanism to Reverse Fibrosis 12:00 pm

Discover how lixudebart, a first-in-class monoclonal antibody, selectively binds to exposed Claudin-1 in fibrotic tissue, blocking fibrotic signaling and breaking down the collagen barrier to preserve or restore organ function in liver, kidney, and lung fibrosis Gain insights into the clinical development of lixudebart, including ongoing and planned Phase 2 trials for kidney and lung…Read more

day: Day Two

Panel & Audience Discussion: Collaborative Strategies for Advancing Antifibrotic Drug Development Across Diverse Disease Indications 4:00 pm

This panel discussion gathers experts from across the various disease indications to discuss what is needed to collectively advance antifibrotic drug development across the broad spectrum of diseases. Expect coverage of: With an increase recognition of the complexity and heterogeneity of fibrotic diseases, will combination therapies be necessary to secure clinical efficacy above the current…Read more

day: Day One